Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2013 2
2014 1
2015 2
2017 1
2019 1
2020 5
2021 4
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Is mammographic density a marker of breast cancer phenotypes?
Kanbayti IH, Rae WID, McEntee MF, Al-Foheidi M, Ashour S, Turson SA, Ekpo EU. Kanbayti IH, et al. Among authors: al foheidi m. Cancer Causes Control. 2020 Aug;31(8):749-765. doi: 10.1007/s10552-020-01316-x. Epub 2020 May 14. Cancer Causes Control. 2020. PMID: 32410205
Response to Induction Neoadjuvant Hormonal Therapy Using Upfront 21-Gene Breast Recurrence Score Assay-Results From the SAFIA Phase III Trial.
AlSaleh K, Al Zahwahry H, Bounedjar A, Oukkal M, Saadeddine A, Mahfouf H, Bouzid K, Bensalem A, Filali T, Abdel-Razeq H, Larbaoui B, Kandil A, Abulkhair O, Al Foheidi M, Errihani H, Ghosn M, Abdel-Aziz N, Arafah M, Boussen H, Dabouz F, Rasool H, Bahadoor M, Ayari J, Kullab S, Nabholtz JM. AlSaleh K, et al. Among authors: al foheidi m. JCO Glob Oncol. 2021 Jun;7:811-819. doi: 10.1200/GO.20.00575. JCO Glob Oncol. 2021. PMID: 34086481 Free PMC article. Clinical Trial.
Combination of palbociclib with adjuvant endocrine therapy for treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer: An experience at two cancer centers in Saudi Arabia.
Al-Foheidi MH, Albeshri AM, Moamenkahan SN, Abdullah AM, Abualola MS, Alharbi MH, Refa AA, Bayer AM, Shaheen AY, Aga SS, Khan MA, Al-Mansour MM, Ibrahim EM. Al-Foheidi MH, et al. Mol Clin Oncol. 2022 Jun 1;17(1):119. doi: 10.3892/mco.2022.2552. eCollection 2022 Jul. Mol Clin Oncol. 2022. PMID: 35747598 Free PMC article.
Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: simulation study.
Yousef CC, Khan MA, Almodaimegh H, Alshamrani M, Al-Foheidi M, AlAbdalkarim H, AlJedai A, Naeem A, Abraham I. Yousef CC, et al. Among authors: al foheidi m. J Med Econ. 2023 Jan-Dec;26(1):394-402. doi: 10.1080/13696998.2023.2183680. J Med Econ. 2023. PMID: 36815700 Free article.
19 results